By Jason Chau
Five Chinese companies including a semiconductor wafer maker and a biotechnology firm, have started marketing their shares ahead of planned Hong Kong listings, which could raise a combined 5.3 billion Hong Kong dollars, equivalent to US$677.8 million.
Three technology companies--Shandong Extreme Vision Technology, Guangdong Huayan Robotics and Epiworld International--have started taking orders for their initial public offerings.
Epiworld, a producer of silicon carbide wafers for semiconductor devices, seeks to raise HK$1.64 billion by selling 21.5 million shares at HK$76.26 each. Huayan Robotics, which makes collaborative robots for industrial and logistical uses, is aiming to raise HK$1.37 billion from a 80.8 million share offering at HK$17.00 each.
Extreme Vision, which develops AI computer vision solution used to allow computers to mimic the human visual system and extract information from images or videos, is also planning to raise HK$499.2 million through a sale of 12.5 million shares at HK$40.00 per share.
Epiworld, a silicon carbide epitaxial foundry, said it plans to use most of its net proceeds to expand its production capacity over the next five years, while the rest would be spent on research and development.
Both Huayan and Extreme Vision said they will use the funds raised for research and development, as well as global marketing and commercialization. Huayan will allocate much of the proceeds to enhancing its intelligent cobots, precision motion platforms and humanoid robot components, while Extreme Vision will direct a significant portion toward building its AI model and related infrastructure.
Separately, two healthcare companies have also began their listing offerings.
Medical imaging device and software maker Hangzhou Diagens Biotechnology is expected to raise HK$899.9 million by selling 8.0 million shares priced between HK$95.60 and HK$112.50. The firm said it will commit most of the net proceeds to further develop and market its core product AI AutoVision, improve its other AI-power medical technologies, research on product candidates and expand its market presence globally.
Beijing Tong Ren Tang Healthcare Investment, a subsidiary of major Hong Kong-listed traditional Chinese medicine group Tong Ren Tang, plans to raise up to HK$897.7 million by offering 108.2 million shares priced between HK$7.30 and HK$8.30. Proceeds will be used to expand its network and repay bank loans.
The planned listings extend a wave of Chinese companies seeking to raise funds in Hong Kong. Despite rising geopolitical uncertainties, sentiment toward China's technology and healthcare sectors remains strong, supported by rapid innovation.
The Hong Kong Exchange recently said nearly 500 listings are already in the pipeline.
All of the offerings are set to close on March 25, with their shares expected to start trading on March 30.
Write to Jason Chau at jason.chau@wsj.com
(END) Dow Jones Newswires
March 19, 2026 23:43 ET (03:43 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
